BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Key C, Layton D, Shakir SAW. Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety. Pharmacoepidem Drug Safe 2002;11:143-8. [DOI: 10.1002/pds.690] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 . Pharmacoepidemiology and drug safety. Pharmacoepidemiol Drug Saf 2002;11:529-44. [PMID: 12426939 DOI: 10.1002/pds.662] [Reference Citation Analysis]
2 Al-Haroni M, Skaug N. Knowledge of prescribing antimicrobials among Yemeni general dentists. Acta Odontol Scand 2006;64:274-80. [PMID: 16945892 DOI: 10.1080/00016350600672829] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
3 Habib B, Tamblyn R, Girard N, Eguale T, Huang A. Detection of adverse drug events in e-prescribing and administrative health data: a validation study. BMC Health Serv Res 2021;21:376. [PMID: 33892716 DOI: 10.1186/s12913-021-06346-y] [Reference Citation Analysis]
4 Kasliwal R, Wilton LV, Cornelius V, Aurich-barrera B, Shakir SAW. Safety Profile of Rosuvastatin: Results of a Prescription-Event Monitoring Study of 11???680 Patients. Drug Safety 2007;30:157-70. [DOI: 10.2165/00002018-200730020-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
5 Aronson JK. Adverse Drug Reactions: History, Terminology, Classification, Causality, Frequency, Preventability. In: Talbot J, Aronson JK, editors. Stephens' Detection and Evaluation of Adverse Drug Reactions. Chichester: John Wiley & Sons, Ltd; 2011. pp. 1-119. [DOI: 10.1002/9780470975053.ch1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Twaites BR, Wilton LV, Shakir SAW. Safety of Zafirlukast: Results of a Postmarketing Surveillance Study on 7976 Patients in England. Drug Safety 2007;30:419-29. [DOI: 10.2165/00002018-200730050-00005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
7 Torre C, Cary M, Borges FC, Ferreira PS, Alarcão J, Leufkens HG, Costa J, Martins AP. Intensive Monitoring Studies for Assessing Medicines: A Systematic Review. Front Med (Lausanne) 2019;6:147. [PMID: 31380375 DOI: 10.3389/fmed.2019.00147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 El Emam K, Samet S, Arbuckle L, Tamblyn R, Earle C, Kantarcioglu M. A secure distributed logistic regression protocol for the detection of rare adverse drug events. J Am Med Inform Assoc 2013;20:453-61. [PMID: 22871397 DOI: 10.1136/amiajnl-2011-000735] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
9 James S, Halliday K, Somers J, Broderick N. A Survey of Non-accidental Injury Imaging in England, Scotland and Wales. Clinical Radiology 2003;58:696-701. [DOI: 10.1016/s0009-9260(03)00225-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
10 Gattellari M, Zwar N, Worthington JM. No difference demonstrated between faxed or mailed prenotification in promoting questionnaire response among family physicians: a randomized controlled trial. Journal of Clinical Epidemiology 2012;65:544-52. [DOI: 10.1016/j.jclinepi.2011.08.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
11 Wilton LV, Key C, Shakir SA. The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England. Drug Saf 2003;26:121-32. [PMID: 12534328 DOI: 10.2165/00002018-200326020-00005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
12 Layton D, Clarke A, Wilton LV, Shakir SAW. Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study. Osteoporos Int 2005;16:490-500. [DOI: 10.1007/s00198-004-1710-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
13 Wetzel D, Himmel W, Heidenreich R, Hummers-pradier E, Kochen MM, Rogausch A, Sigle J, Boeckmann H, Kuehnel S, Niebling W, Scheidt-nave C. Participation in a quality of care study and consequences for generalizability of general practice research. Family Practice 2005;22:458-64. [DOI: 10.1093/fampra/cmi022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
14 Poppelaars FAM, Adèr HJ, Cornel MC, Henneman L, Hermens RPMG, van der Wal G, Kate LPT. Attitudes of Potential Providers Towards Preconceptional Cystic Fibrosis Carrier Screening. J Genet Counsel 2004;13:31-44. [DOI: 10.1023/b:jogc.0000013193.80539.d1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
15 Layton D, Riley J, Wilton LV, Shakir SA. Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol 2003;55:166-74. [PMID: 12580988 DOI: 10.1046/j.1365-2125.2003.01763.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
16 Eguale T, Tamblyn R, Winslade N, Buckeridge D. Detection of Adverse Drug Events and Other Treatment Outcomes Using an Electronic Prescribing System: . Drug Safety 2008;31:1005-16. [DOI: 10.2165/00002018-200831110-00005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
17 Gupta P, Anvikar AR, Valecha N, Gupta YK. Pharmacovigilance practices for better healthcare delivery: knowledge and attitude study in the national malaria control programme of India. Malar Res Treat 2014;2014:837427. [PMID: 25302133 DOI: 10.1155/2014/837427] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
18 Fadare JO, Adeoti AO, Desalu OO, Enwere OO, Makusidi AM, Ogunleye O, Sunmonu TA, Truter I, Akunne OO, Godman B. The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians. Expert Rev Pharmacoecon Outcomes Res 2016;16:639-50. [PMID: 26567041 DOI: 10.1586/14737167.2016.1120673] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
19 Layton D, Wilton LV, Shakir SAW. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study. Eur J Clin Pharmacol 2004;60:489-501. [DOI: 10.1007/s00228-004-0788-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
20 Layton D, Shakir S. Prescription-Event Monitoring (PEM): The Evolution to the New Modified PEM and its Support of Risk Management. In: Andrews EB, Moore N, editors. Mann's Pharmacovigilance. Oxford: John Wiley & Sons, Ltd; 2014. pp. 359-84. [DOI: 10.1002/9781118820186.ch22] [Cited by in Crossref: 8] [Article Influence: 1.0] [Reference Citation Analysis]